logo-loader
RNS
viewFrontier IP Group PLC

Exscientia collaboration with Rallybio

/**/ ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #000000 }visited{ color: fuchsia } .aa{size:595.0pt 842.0pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.aa{}p.bs{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;margin-bottom:0cm;margin-bottom:.0001pt;line-height:normal}span.bt{font-weight: bold}p.bu{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;line-height: normal; margin-bottom: 0cm; text-align: right}p.bv{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;line-height: normal; margin-bottom: 0cm; text-align: center}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;}span.bm{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.bw{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;font-weight: bold}span.bl{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black} p.bx{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;font-div: italic}span.by{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold; text-transform: uppercase}p.bz{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none;font-weight: bold; line-height: 13.8pt; margin-bottom: 10.0pt}span.bh{font-size:11.0pt;font-family:"Calibri","sans-serif"}table.ca{margin-left:1.5pt;border-collapse:collapse;border:none}tr.ba{height:13.0pt}td.bd{width:297.0pt;border:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:13.0pt}p.cb{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none;margin-bottom:8.0pt;line-height:107%}span.cc{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold; line-height: 107%}td.bb{width:148.25pt;border:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:13.0pt} span.cd{font-size:11.0pt;line-height:107%; font-family:"Calibri","sans-serif"}tr.aw{height:54.9pt}td.ay{width:297.0pt;border:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:54.9pt}span.ce{font-family:"Calibri","sans-serif";color:blue;text-decoration:underline;font-size:11.0pt;line-height:107%}td.ax{width:148.25pt;border:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:54.9pt}tr.at{height:25.95pt}td.av{width:297.0pt;border:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:25.95pt}td.au{width:148.25pt;border:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:25.95pt}tr.ap{height:15.5pt}td.ar{width:297.0pt;border:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:15.5pt} span.as{font-size:11.0pt;line-height:107%;font-family:"Calibri","sans-serif"}td.aq{width:148.25pt;border:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:15.5pt}p.cf{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none;font-weight: bold; line-height: 107%; margin-bottom: 8.0pt}span.cg{font-family:"Calibri","sans-serif";color:blue;text-decoration:underline;font-size:11.0pt;line-height:107%; color:#0070C0}span.ch{font-family:"Calibri","sans-serif";color:blue;text-decoration:underline;font-size:11.0pt; line-height:107%;color:#0070C0}span.al{font-size:11.0pt;line-height:107%;font-family:"Calibri","sans-serif"; color:#0070C0}span.ci{font-family:"Calibri","sans-serif";color:blue;text-decoration:underline;font-size: 11.0pt; line-height: 107%; text-decoration: none}span.cj{font-size:11.0pt; font-family:"Calibri","sans-serif"}span.ai{font-size:11.0pt;font-family:"Calibri","sans-serif";color:#0070C0}span.ck{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold; text-transform: uppercase} span.af{font-size:11.0pt;font-family: "Calibri","sans-serif"}span.ae{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}p.cl{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none;margin-top:12.1pt;margin-right:0cm;margin-bottom:12.1pt; margin-left:0cm;background:white}span.cm{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}span.cn{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.co{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none;margin-top:13.2pt;margin-right:0cm;margin-bottom:13.2pt; margin-left:0cm;background:white} /**/
RNS Number : 6261G
Frontier IP Group plc
25 July 2019
 

RNS Reach

AIM: FIPP

25 July 2019

 

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

Portfolio news - Exscientia enters broad rare disease drug discovery collaboration with Rallybio

 

 

Frontier IP, a specialist in commercialising university intellectual property, is pleased to note the following announcement from portfolio company Exscientia ("Exscientia" or the "Company"), a world leader in artificial intelligence ("AI") drug discovery, that it has entered into a drug discovery collaboration with Rallybio.

 

Rallybio is a US-based drug development company aiming to transform the lives of patients with rare diseases.

 

Exscientia's other partnerships include collaborations with Celgene, GSK, Roche, Sanofi, GT Apeiron and Evotec. Frontier IP currently holds a 3.25 per cent stake in the Company.

 

 

Exscientia statement in full:

 

EXSCIENTIA ENTERS BROAD RARE DISEASE DRUG DISCOVERY COLLABORATION WITH RALLYBIO

Joint venture will initiate drug discovery programs targeting rare diseases using AI

 

Exscientia, a world-leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered into a collaboration with Rallybio, a U.S.-based drug development company, which aims to transform lives of patients with rare diseases. The collaboration will combine Exscientia's AI drug discovery platform with Rallybio's expertise in rare disease drug development to accelerate the discovery of small molecule drug therapeutics for undisclosed rare disease indications.

 

It is estimated that there are between 7,000 and 8,000 rare diseases, which affect 25 to 30 million Americans and 30 to 40 million European Union citizens. These diseases pose unique challenges to the healthcare systems around the world because they require specific medical expertise and significant drug research, diagnostic and screening capabilities in order to treat these patients.

 

Alongside the team of world-class scientists from Rallybio, Exscientia will apply its cutting-edge, Centaur Chemist™, AI drug discovery platform to design pre-clinical drug candidates for the joint venture, RE Ventures, owned equally by Exscientia and Rallybio. The financial details of the collaboration are not disclosed.

 

"There is a huge potential for artificial intelligence to revolutionise and democratise rare disease drug discovery. AI can fast track, simplify and lower the price of research and we are thrilled to be partnering with Rallybio to achieve this. The future of drug discovery in rare diseases is to be able to address the need for precision engineered drugs at scale and our collaboration with Rallybio is the first step in this direction," said Andrew Hopkins, CEO of Exscientia.

 

"Our joint venture brings together Exscientia's industry-leading AI drug discovery capabilities with Rallybio's expertise in rare disease drug development," said Steve Uden, Chief Operating Officer of Rallybio. "We believe this collaboration will accelerate the development of life-transforming therapies for patients suffering from severe and rare disorders."

 

 

Exscientia statement ends 

 

 

ENQUIRIES

 

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser and Broker)

T: 0203 328 5656

Nick Athanas / Nicholas Chambers (Corporate Finance)

Amrit Nahal (Equity Sales)


 

Exscientia Limited  

Corporate enquiries:


Mark Swindells, Chief Operating Officer

Company website: www.exscientia.co.uk

Twitter: www.twitter.com/exscientialtd

 

[email protected]

 

 

Exscientia media enquiries:

Edelman

 

 

[email protected]

Sesh Rahim

+44(0) 203 047 4207

Camille Oster

+44(0) 7812660934

 

NOTES FOR EDITORS

 

 

About Exscientia

 

Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches.

 

Exscientia's innovative Centaur Chemist™ platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds are automatically designed and prioritised for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development.

 

Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and pharmacokinetic criteria.

 

As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour.

 

Exscientia is collaborating with several leading pharmaceutical and life sciences companies, including GSK, Sanofi and Evotec.

 

Exscientia has its headquarters in Oxford, UK, with offices in the UK, USA and Japan. For more information visit www.exscientia.co.uk or follow us on Twitter @exscientialtd

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

ABOUT RNS REACH ANNOUNCEMENTS

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAEZLFLKDFEBBE

Quick facts: Frontier IP Group PLC

Price: 57.5

Market: AIM
Market Cap: £24.4 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Frontier IP focused on further industrial engagement across portfolio

Neil Crabb, chief executive of Frontier IP Group Plc (LON:FIPP) caught up with Proactive's Andrew Scott following the release of their half-year report. Frontier’s portfolio includes AI drug researcher Exscientia which secured a €15mln strategic investment from drug discovery company...

on 29/3/18